Isomorphic Labs Partners with MSD in the Fight Against Cancer Using AI

Isomorphic Labs, a subsidiary of Alphabet, and MSD are planning a joint research program for cancer drug discovery that combines artificial intelligence and pharmaceutical data. The partners will seek therapeutic candidates consisting of small molecules, targeting an oncological target deemed strategic.
Isomorphic Labs announces $5 billion
Earlier this week, Isomorphic Labs announced a $5 billion Series C funding round. Greenoaks co-led the operation alongside Sequoia Capital. Andreessen Horowitz is among the participants, along with several other new investors.
Alphabet also made a significant investment. Existing investors participated: Thrive Capital, MGX, GV, CapitalG, Temasek, and the British Sovereign AI Fund.
MSD emphasizes laboratory coordination
For George Addona, Senior Vice President of Discovery, Preclinical Development, and Translational Medicine at MSD Research Laboratories, the successful use of AI and machine learning in molecular invention requires a close alignment between laboratory experimentation and computational work. He specifies that MSD will provide its internal data and discovery expertise, while Isomorphic Labs will contribute through modeling and computation. The stated goal of the executive is to find new methods to produce better therapeutic candidates more quickly.
Le brief IA que les pros lisent chaque soir
Les 7 actus IA du jour, décryptées en 5 min. Gratuit.
Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.
Choisissez votre rythme
Gratuit · Pas de spam · Désabonnement en 1 clic
Sarah Skerratt, Director of Research at Isomorphic Labs, describes a challenging program that will apply the generative and predictive capabilities of IsoDDE. She expects significant advancements in discovery from this engine. She also presents this collaboration as an expression of a shared commitment to innovate for patients with unmet needs.
Molecule design and MSD's responsibilities
To design the molecules, Isomorphic Labs plans to integrate MSD's datasets into IsoDDE, its drug design engine. The company will utilize in silico prediction, meaning experiments conducted or simulated on computers for pharmaceutical research.
If drugs emerge from the program, their preclinical and then clinical development will fall to MSD. The group will also handle their manufacturing and commercialization.
The agreement includes an initial payment from MSD to Isomorphic Labs. Additional payments may follow, contingent upon reaching specified milestones in research and development, as well as in regulatory and commercial aspects.
Brief IA — L'actualité IA en français
L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.